Company
Oncimmune Holdings PLC
LON:ONC
Oncimmune Holdings PLC is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The company has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
139 stories · page 1 of 2
Oncimmune says 2023 will be an 'inflexion year' for the business
"The commercial pipeline has grown well under our new chief business officer who was appointed in September 2021,” said CEO Adam Hill
Oncimmune appoints new chair, updates on trading
“Medicare coverage will also ensure physicians have access to the NodifyCDT lung nodule test"
Oncimmune receives 2022 Queen's Award for Enterprise
The award recognises Oncimmune as a leading developer of applied immunodiagnostics for the early detection of disease
Oncimmune lands new contracts for its ImmunoINSIGHTS services
It has inked deals with two US drug developers to provide scientific feedback on the treatments they are developing
Oncimmune lands follow-on Covid study contract
The unnamed customer is a “world-leading” medical research group based in the US, investors were told
Oncimmune Holdings announces its third deal of the week
This latest agreement is with an unnamed top ten pharmaceutical company
Oncimmune inks second partnership deal in two days
It is teaming up with Synexa Life Sciences to deliver autoantibody screening
Oncimmune teams up with health company owned by Google parent in long Covid collaboration
The AIM-listed immunodiagnostics firm is teaming up with Verily Life Sciences
Oncimmune lung cancer diagnostic wins green light from second Spanish regional health authority
The latest news is seen as an important development for the company's distributor, Sabartech
Oncimmune Holdings' ImmunoINSIGHTS operation lands contract profile patients with skin condition
It has been given the task of profiling people with chronic idiopathic urticaria (CIU), a skin condition that is also sometimes referred to as ‘hives’
Oncimmune says ImmunoINSIGHTS pharma services business delivered a record quarter
“The potential for ImmunoINSIGHTS has been validated by my network of commercial professionals and pharma and biotech contacts," said the company's chief business officer, Cameron Barnard
Archive
FIVE at FIVE: Legal German weed, money on the WIND, the Footsie, Hochschild keeps its mines – and the earthly benefits of space investing
Here’s Proactive’s round-up of the day’s news with helpful links taking you our up-to-the-minute news analysis.
Proactive news headlines: Gaming Realms, XLMedia, Greencoat UK Wind ...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune sees significant momentum driven by ImmunoINSIGHTS service
The autoantibody profiling service developed a pipeline of over 160 commercial opportunities last financial year and continues to secure follow-on contracts with customers of strategic importance
Oncimmune signs agreement with big pharma group for autoimmune diseases profiling
Oncimmune will utilise its autoimmune disease characterisation panel to explore the profiles of patients with four diseases
Oncimmune hails three-year follow-up data from landmark early detection lung cancer trial
Readers of the peer-reviewed article were told late-stage cancers and deaths were lower in the group of patients assessed using the company’s diagnostic
Proactive news headlines: Oncimmune, Remote Monitored Systems, Record, Bidstack Group...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune signs deal with world-renowned Dana-Farber Cancer Institute
The firm's SeroTag technology will be used to assess for resistance to checkpoint inhibitor drugs and chemotherapy
Oncimmune technology used by Cedars-Sinai researchers in breakthrough COVID-19 research
The team found the virus affects men and women differently, which could have an impact on the way second and third-generation vaccines are developed
Oncimmune looking to ImmunoINSIGHTS to deliver another step-change in revenue growth
If things go as expected, the first quarter of the current fiscal year should see the company secure roughly half the revenues the market expects for the whole year
Proactive news headlines: MBH Corporation, Oncimmune, Eckoh, Coinsilium Group...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune strikes deal with partner to take back China and Hong Kong rights to its technology
The company said the agreement with Genostics would also allow it to “pursue the optimum route to market in this important territory"
Archive
Proactive news headlines: Oncimmune, Alien Metals, Cornerstone FS, Gore Street Energy Storage...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune Holdings wins COVID-19 contracts with Roche and Cedars-Sinai Medical Center
They will use an infectious disease panel that can help predict the severity of COVID-19 along with the potential effectiveness of vaccines and other drugs used to treat it
Oncimmune raises £9mln to expand ImmunoINSIGHTS business
Proceeds will fund the biotech services business to expand amid high commercial demand, to double capacity this year, and, double it again next year.
Oncimmune Holdings sees sixfold increase in half-year revenues
ImmunoINSIGHTS commercial activity has been strong, with seven contracts signed since the beginning of June.
Oncimmune delivering top-line growth
Oncimmune is a specialist in the field of immunodiagnostics
Oncimmune says Dr Cheung To, of significant shareholder Genostics, has stepped down as a non-executive director
Genostics remains Oncimmune's exclusive partner in China and continues to work closely with Oncimmune to gain market entry
Oncimmune says team plays important role in helping define a new approach to rheumatoid arthritis
Researchers from the ImmunoINSIGHTS operation worked alongside scientists from Roche and University Medical Center Utrecht
Oncimmune higher as it sees commercial traction for lung blood test; successful NICE assessment would support wider adoption
The group has landed two early commercial deals, while its technology is being formally looked at by the National Institute for Health and Care Excellence (NICE)
Oncimmune Holdings signs master service agreement with California-based immunotherapy specialist
It will profile patient plasma samples and assess treatment candidates discovered using the Augmenta's SingleCyte and DeepGrid platforms
Oncimmune Holdings generating a growing pipeline of opportunities
Chief executive Adam Hill said he expects the business to generate "substantial further growth"
Oncimmune says lung blood test part of a clinical study assessing the screening potential of the technology
“Oncimmune is committed to producing further evidence that supports both adoption and reimbursement decisions in the markets where EarlyCDT Lung is available,” said chief executive Adam Hill
Oncimmune welcomes independent validation of its lung blood test
The data were presented in detail at the recent American College of Chest Physicians (CHEST) annual meeting
Archive
Proactive news headlines: Oncimmune, BlueRock Diamonds, Ncondezi Energy, Capital Limited …
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune links up with world-renowned Cedars-Sinai for COVID-19 programme
“We expect to announce further development collaborations and contracts over the coming months to be followed by contracts with biopharmaceutical companies once the COVID-19 panel is fully validated," said chief executive, Adam Hill
Oncimmune Holdings receives backing to produce “comprehensive diagnostic tool” for COVID-19
“Oncimmune has been in discussion for some months now to utilise its differentiated technical knowledge to develop a comprehensive diagnostic tool capable of characterising the immune system's response to COVID-19 and, as a consequence, bei
Oncimmune inks collaboration with Genentech that broadens the "commercial footprint” of its ImmunoINSIGHTS service business
"Genentech is a pre-eminent biotechnology company, considered a leader in the biotech industry today,” said chief executive, Dr Adam Hill
Oncimmune boost as study shows its blood test could play a 'highly cost-effective' role in lung cancer surveillance
Academics looked at the deployment of the EarlyCDT Lung test in combination with computed tomography
Oncimmune Holdings says ImmunoINSIGHTS service "building momentum" following fourth significant partnership in just four months
The programme will see the deployment of the biomarker discovery engine, SeroTag
Oncimmune rises after its lung cancer test is featured on ITV News report
EarlyCDT Lung enables earlier and accurate diagnosis of lung cancer in high-risk patients that could mean an intervention is offered early
Oncimmune says abstracts support the use of lung cancer test
The latest data was taken from a successful large-scale trial
Oncimmune says leading lung disease-focused scientific publication has published results from the ECLS trial
The Early detection of Cancer of the Lung Scotland (ECLS) trial was delivered by the Universities of Dundee and St Andrews with NHS Tayside, and co-funded by Oncimmune, the Scottish Chief Scientist Office and the Scottish Government
Oncimmune Roche collaboration expanded substantially
"Our ongoing relationship with Roche is providing us with the opportunity to further contribute to the understanding of individual patient responses to immunotherapy through immune profiling,” said chief executive, Dr Adam Hill
Oncimmune team contributes "world-class science" to rheumatoid arthritis research
The firm's ImmunoINSIGHTS team was integral to a paper published in the journal ‘Arthritis Research & Therapy’
Oncimmune Holdings lung cancer detection blood test gets marketing go ahead in Brazil
The country's Agência Nacional de Vigilância Sanitária gave the green light to the EarlyCDT Lung blood test
Oncimmune is building momentum in key areas says broker finnCap
The City broker's forecasts are unchanged, while it has reiterated its 150p share price target
Oncimmune says revenues in line
Oncimmune was upbeat about its prospects after it confirmed revenues in the fiscal year just ended would be in line with the market's expectations
Oncimmune signs major immune profiling contract with Swiss pharma giant Roche
The contract involves a substantial upfront payment said the AIM-listed group and starts immediately
Archive
Small Cap Wrap - Oncimmune ; ClearStar ;NQ Minerals; Feedback
Banquet Buffet Oncimmune 100p £63.5m (AIM:ONC) The global immunodiagnostics group today announces that it has signed a foothill contract to utilise the Company's Early CDT Lung panel...
Oncimmune teams up with one of the world’s largest pharmaceuticals companies to screen for lung cancer
The latest agreement is one of a series of deals inked in the last two months that showed the “full breadth” of the firm’s commercial offering, said chief executive Adam Hill
Oncimmune's study data to be featured at prestigious cancer research conference
The presentation will be the first time that the clinical utility of autoantibodies has been presented at the American Society of Clinical Oncology conference
Archive
Small Cap Wrap - Oncimmune Holdings; Angle; Ncondezi; Galantas Gold and more ...
Oncimmune Holdings 87.5p £55.56m (AIM:ONC) The global immunodiagnostics group, today announces it has signed an antigen targeting collaboration to support drug development with a leading US biopharmaceutical company which is developing nove
Archive
Proactive news headlines: Oncimmune, Galantas Gold, Vast Resources, Angling Direct, ANGLE …
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune agrees drug development collaboration with leading US biopharma group
The UK group will support its new partner with antigen targeting using its biomarker discovery engine, SeroTag
Small Cap Wrap - Frontier IP Group; 88 Energy Ltd; Oncimmune Holdings and more....
Frontier IP Group (LON:FIPP) 65p £32.9m Frontier IP, a specialist in commercialising intellectual property, has raised its equity stake in portfolio company Celerum Limited from 10 per cent to 33.8 per cent.
Small Cap Wrap - Frontier IP Group; 88 Energy Ltd; Oncimmune Holdings and more....
Frontier IP Group (LON:FIPP) 65p £32.9m Frontier IP, a specialist in commercialising intellectual property, has raised its equity stake in portfolio company Celerum Limited from 10 per cent to 33.8 per cent.
Oncimmune’s early-stage lung cancer test gets NICE backing
The clinical advisory body said the EarlyCDT Lung test could bring a potential benefit of early treatment and improved outcomes, as well as reducing waiting times
Oncimmune jumps as it praises American partner as lung cancer product launches in US
Biodesix Inc “exceeded our expectations”, CEO Adam Hill said
Oncimmune awarded the 'Winning in Business in Spain' award at the Department for International Trade's UK-Spain Business Awards
The awards celebrate the extensive commercial relationships between the United Kingdom and Spain
Oncimmune eyes US launch for lung cancer diagnostic; has strong deal pipeline
Partner Biodesix will unveil EarlyCDT Lung to the American medical audience next month as part of a five-year agreement worth US$28mln
Oncimmune says report hails "cost-effective" lung cancer diagnostic
A study, led by Leeds University Academic Unit of Health Economics, said the EarlyCDT Lung test sped up the process of identifying the disease
Oncimmune joins Oxford-based liver cancer diagnostic consortium
The programme, brought together by the Oxford Centre for Early Cancer Detection, aims to understand how the liver changes while the tumour develops
Oncimmune has “substantially reduced” commercial risk for EarlyCDT cancer test, says broker
In a note initiating the biotech firm with a price target of 150p, the broker forecast £400,000 in revenues for the first half of the 2020 financial year and £800,000 for the second half
Oncimmune Holdings draws down final tranche of IPF facility
The new funds will be used to bankroll its commercial push based around its EarlyCDT technology, which is used to detect cancer
Oncimmune clinches commercialisation deal with Biodesix for EarlyCDT test
The biotechnology group said the deal, originally announced in June, will be worth up to US$28mln over the next five years
Oncimmune targets “material revenues in 2020 and beyond"
It has been a pivotal period for the cancer diagnostics specialist
Oncimmune welcomes NHS review of cancer screening programmes
The review is aiming to increase earlier cancer diagnosis among patients, something the company is trying to achieve with its EarlyCDT lung cancer test
Oncimmune makes three "experienced and seasoned" hires as commercial development of its cancer diagnostic gets into full swing
They are Professor Tariq Sethi, Matthew Luttrell and Cléa Rosenfeld
Oncimmune Holdings secures €8.5mln credit facility that will allow it “drive commercial adoption” of its lung cancer diagnostic
As well as funding the push to take the EarlyCDT Lung device to market after a successful large-scale trial, the additional cash will also be used to fund research on other indications for the technology such as liver cancer
Oncimmune higher as it presents positive trial data at lung cancer conference
The diagnostics firm had presented its data at the World Conference for Lung Cancer in Barcelona
Archive
Proactive news snapshot: Kavango Resources, Motif Bio, Shanta Gold...
A glance at some of the day's highlights from the Proactive Investors newswire
Oncimmune Holdings hails latest Spain deal for Lung cancer detection device
Local distributor Sabartech has inked an agreement with Vithas Group, which operates 48 hospitals and medical centres
Russian drug giant strikes multi-million-pound deal to use Oncimmune’s EarlyCDT Lung cancer test
R-Pharm has the exclusive right to use EarlyCDT Lung in Russia for the next five years, and Oncimmune expects the partnership will generate revenues of at least £5mln
Archive
Proactive news snapshot: Argo Blockchain, ValiRx, Arc Minerals, Directa Plus ...
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Union Jack Oil, Oncimmune, Ariana Resources …
A glance at some of the day's highlights from the Proactive Investors newswire